Overview

• Federal grand jury charges Hoau-Yan Wang with major fraud, wire fraud, and making false statements.
• Wang allegedly manipulated data in grant applications, securing $16 million from NIH between 2017 and 2021.
• The fraudulent research supported early development of simufilam, an experimental Alzheimer's drug.
• Cassava Sciences, the pharmaceutical company involved, denies Wang's involvement in later-stage trials.
• Wang faces decades in prison if convicted on all charges.